Patient characteristics and census tract level nSES
| . | Total . | White . | Hispanic . | Black . | Asian . | Other/unknown . |
|---|---|---|---|---|---|---|
| n | 3146 | 2356 (74.9%) | 411 (13.1%) | 189 (6%) | 116 (3.7%) | 74 (2.4%) |
| Sex | ||||||
| Female | 1274 | 913 (71.7%) | 175 (13.7%) | 93 (7.3%) | 57 (4.5%) | 36 (2.8%) |
| Male | 1872 | 1443 (77.1%) | 236 (12.6%) | 96 (5.13%) | 59 (3.1%) | 38 (2%) |
| Age | ||||||
| Mean (SD) | 62.6 (14.6) | 64.2 (13.9) | 57.4 (15.7) | 57.8 (15.6) | 57.9 (16.5) | 60.2 (13.3) |
| Median | 64.6 | 66.2 | 59.1 | 59.3 | 60.3 | 60.8 |
| Range | 18.1-100.7 | 18.6-100.7 | 18.1-96.2 | 21.9-98.6 | 18.7-91.3 | 30.4-83.2 |
| Diagnosis | ||||||
| DLBCL | 917 | 642 (70%) | 143 (15.6%) | 65 (7.1%) | 47 (5.1%) | 20 (2.2%) |
| FL | 698 | 540 (77.4%) | 87 (12.5%) | 34 (4.9%) | 20 (2.9%) | 17 (2.4%) |
| MCL | 417 | 364 (87.3%) | 28 (6.7%) | 8 (1.9%) | 6 (1.44%) | 11 (2.6%) |
| MZL | 287 | 214 (74.6%) | 36 (12.5%) | 18 (6.3%) | 9 (3.1%) | 10 (3.5%) |
| TCL | 259 | 164 (63.3%) | 43 (16.6%) | 33 (12.7%) | 13 (5%) | 6 2.3%) |
| Misc. | 235 | 191 (81.3%) | 19 (8.1%) | 14 (6%) | 5 (2.1%) | 6 (2.6%) |
| High-grade BCL | 205 | 141 (68.8%) | 42 (20.5%) | 8 (3.9%) | 11 (5.4%) | 3 (1.5%) |
| Composite | 118 | 91 (77.12%) | 13 (11%) | 9 (7.6%) | 4 (3.4%) | 1 (0.9%) |
| Gray zone lymphoma | 10 | 9 (90%) | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) |
| ADI (Quartiles) | ||||||
| Q1 (0-25) | 774 | 615 (79.5%) | 52 (6.7%) | 23 (3%) | 58 (7.5%) | 26 (3.4%) |
| Q2 (26-50) | 889 | 700 (78.7%) | 97 (10.9%) | 48 (5.4%) | 30 (3.4%) | 14 (1.6%) |
| Q3 (51-75) | 753 | 544 (73.6%) | 123 (16.3%) | 52 (6.9%) | 14 (1.9%) | 20 (2.7%) |
| Q4 (76-100) | 472 (16.3%) | 295 (62.5%) | 112 (23.7%) | 52 (11%) | 5 (1.1%) | 8 (1.7%) |
| ADI (Continuous) | ||||||
| Range | 1-100 | 1-100 | 2-100 | 1-100 | 1-93 | 1-95 |
| Mean (SD) | 45.5 (26.2) | 43.4 (25.4) | 57.2 (25.8) | 57.9 (26) | 30.2 (23.1) | 39.8 (27.1) |
| Median | 44 | 41 | 59.5 | 58 | 22 | 38 |
| . | Total . | White . | Hispanic . | Black . | Asian . | Other/unknown . |
|---|---|---|---|---|---|---|
| n | 3146 | 2356 (74.9%) | 411 (13.1%) | 189 (6%) | 116 (3.7%) | 74 (2.4%) |
| Sex | ||||||
| Female | 1274 | 913 (71.7%) | 175 (13.7%) | 93 (7.3%) | 57 (4.5%) | 36 (2.8%) |
| Male | 1872 | 1443 (77.1%) | 236 (12.6%) | 96 (5.13%) | 59 (3.1%) | 38 (2%) |
| Age | ||||||
| Mean (SD) | 62.6 (14.6) | 64.2 (13.9) | 57.4 (15.7) | 57.8 (15.6) | 57.9 (16.5) | 60.2 (13.3) |
| Median | 64.6 | 66.2 | 59.1 | 59.3 | 60.3 | 60.8 |
| Range | 18.1-100.7 | 18.6-100.7 | 18.1-96.2 | 21.9-98.6 | 18.7-91.3 | 30.4-83.2 |
| Diagnosis | ||||||
| DLBCL | 917 | 642 (70%) | 143 (15.6%) | 65 (7.1%) | 47 (5.1%) | 20 (2.2%) |
| FL | 698 | 540 (77.4%) | 87 (12.5%) | 34 (4.9%) | 20 (2.9%) | 17 (2.4%) |
| MCL | 417 | 364 (87.3%) | 28 (6.7%) | 8 (1.9%) | 6 (1.44%) | 11 (2.6%) |
| MZL | 287 | 214 (74.6%) | 36 (12.5%) | 18 (6.3%) | 9 (3.1%) | 10 (3.5%) |
| TCL | 259 | 164 (63.3%) | 43 (16.6%) | 33 (12.7%) | 13 (5%) | 6 2.3%) |
| Misc. | 235 | 191 (81.3%) | 19 (8.1%) | 14 (6%) | 5 (2.1%) | 6 (2.6%) |
| High-grade BCL | 205 | 141 (68.8%) | 42 (20.5%) | 8 (3.9%) | 11 (5.4%) | 3 (1.5%) |
| Composite | 118 | 91 (77.12%) | 13 (11%) | 9 (7.6%) | 4 (3.4%) | 1 (0.9%) |
| Gray zone lymphoma | 10 | 9 (90%) | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) |
| ADI (Quartiles) | ||||||
| Q1 (0-25) | 774 | 615 (79.5%) | 52 (6.7%) | 23 (3%) | 58 (7.5%) | 26 (3.4%) |
| Q2 (26-50) | 889 | 700 (78.7%) | 97 (10.9%) | 48 (5.4%) | 30 (3.4%) | 14 (1.6%) |
| Q3 (51-75) | 753 | 544 (73.6%) | 123 (16.3%) | 52 (6.9%) | 14 (1.9%) | 20 (2.7%) |
| Q4 (76-100) | 472 (16.3%) | 295 (62.5%) | 112 (23.7%) | 52 (11%) | 5 (1.1%) | 8 (1.7%) |
| ADI (Continuous) | ||||||
| Range | 1-100 | 1-100 | 2-100 | 1-100 | 1-93 | 1-95 |
| Mean (SD) | 45.5 (26.2) | 43.4 (25.4) | 57.2 (25.8) | 57.9 (26) | 30.2 (23.1) | 39.8 (27.1) |
| Median | 44 | 41 | 59.5 | 58 | 22 | 38 |
BCL, B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; SD, standard deviation; TCL, T-cell lymphoma.